Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price CutsInvestors Business Daily • 08/29/23
Merck, Amgen, AbbVie products among first 10 drugs selected for Medicare price negotiationsMarket Watch • 08/29/23
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)Business Wire • 08/29/23
Dow Jones Drug Giant Merck, Google Stock, Mastercard In Or Near Buy ZonesInvestors Business Daily • 08/28/23
Merck and Eisai say late-stage trial of treatment for head and neck cancer did not meet goalsMarket Watch • 08/25/23
Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616Business Wire • 08/25/23
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaBusiness Wire • 08/25/23
LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate CancerBusiness Wire • 08/24/23
Cancer drug stocks soar after Roche accidentally releases positive interim lung cancer trial resultsProactive Investors • 08/23/23
Is Merck's Long-Term Investment Brilliance Unshaken By COVID-19 Drug Sales Slump?Seeking Alpha • 08/21/23
Dividend Lovers Bet Big on 6 ‘Strong Buy' Goldman Sachs Conviction List Picks for Rest of 202324/7 Wall Street • 08/21/23
Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell CarcinomaBusiness Wire • 08/18/23